Greenwich LifeSciences, Inc.(GLSI)

$27.32▲1.01 (3.84%)

Chart

Greenwich LifeSciences, Inc.(GLSI)

NASDAQ

$27.32▲1.01 (3.84%)

Chart Studio

GLSI(GLSI)

GLSI

Overview Intelligence Chart Historical Prices Fundamentals Key Metrics Earnings Growth Analysts News Financials Insiders Institutional

GLSI 50 articles

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

globenewswire.com·Apr 30

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

globenewswire.com·Apr 30

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

globenewswire.com·Apr 23

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

globenewswire.com·Apr 23

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

globenewswire.com·Apr 22

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

globenewswire.com·Apr 22

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

globenewswire.com·Apr 20

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

globenewswire.com·Apr 20

Greenwich LifeSciences Provides Update on Financing Strategy

globenewswire.com·Apr 14

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

seekingalpha.com·Apr 7

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

globenewswire.com·Apr 7

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

defenseworld.net·Mar 27

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

globenewswire.com·Mar 19

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

globenewswire.com·Mar 18

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

globenewswire.com·Mar 17

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

globenewswire.com·Mar 16

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy?

defenseworld.net·Mar 10

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

globenewswire.com·Mar 3

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

globenewswire.com·Feb 24

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

prnewswire.com·Jan 30

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

globenewswire.com·Jan 27

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

globenewswire.com·Jan 22

Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX)

defenseworld.net·Jan 18

Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares

defenseworld.net·Jan 6

Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT)

defenseworld.net·Jan 5

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

globenewswire.com·Dec 29

What's Going On With Greenwich LifeSciences Friday?

feeds.benzinga.com·Dec 26

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

globenewswire.com·Dec 22

Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

benzinga.com·Dec 15

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

globenewswire.com·Dec 15

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

globenewswire.com·Dec 8

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

globenewswire.com·Dec 3

3 Stocks to Buy for a Volatile End to 2025

investorplace.com·Nov 9

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

globenewswire.com·Oct 9

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

globenewswire.com·Oct 2

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

globenewswire.com·Sep 30

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

globenewswire.com·Sep 18

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

globenewswire.com·Sep 10

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

globenewswire.com·Aug 20

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

globenewswire.com·Aug 19

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

globenewswire.com·Aug 13

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

globenewswire.com·Aug 11

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

globenewswire.com·Apr 3

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

globenewswire.com·Apr 2

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

globenewswire.com·Mar 27

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

globenewswire.com·Mar 17

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

globenewswire.com·Feb 10

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

globenewswire.com·Jan 29

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

globenewswire.com·Jan 27

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

globenewswire.com·Jan 23

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance